1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Cancer Drug News 23 NOVEMBER 2015

Cancer Drug News 23 NOVEMBER 2015

  • November 2015
  • -
  • Espicom Business Intelligence
  • -
  • 12 pages

Industry Trend Analysis - Pfizer Laying Strong Foundations For Long-Term Oncology Growth
Industry Brief - Kadcyla Price Remains Too High For NICE
Industry Brief - Kyprolis Gains EU Approval For Combination Use In Relapsed MM
Industry Trend Analysis - Crowded MM Market Will Provide Challenge For Ninlaro
Industry Brief - FDA Grants ODD To Marizomib In Malignant Glioma
Industry Brief - ZAI Lab/Hanmi Sign Chinese Licensing Deal To Develop EGFr-Targeted LC Therapy
Industry Brief - Xalkori Significantly Prolongs PFS In East Asian Phase III Study For ALK-Positive NSCLC
Industry Trend Analysis - Clovis Rociletinib Slip Solidifies AstraZeneca's Position
Industry Trend Analysis - CDx Evolving With Increased Precision Medicine Focus
Industry Brief - FDA Accepts For Priority Review Opdivo sBLA In RCC
Industry Brief - Morphotek Signs Radioimmunotherapy Pact With University Of Gothenburg
Industry Brief - Chugai Receives Japanese Approval For Additional Xeloda Indication
Industry Brief - Threshold/Merck KGaA Enter Evofosfamide Co-Promotion Agreement
Industry Brief - Tafinlar+Mekinist Receives Regular FDA Approval For MM
Industry Brief - FDA Grants Breakthrough Therapy Designation To Avelumab For MCC
Industry Brief - Sandoz' Third Biosimilar Application Accepted By The FDA
Industry Brief - Cancer Conferences - February 2016

Table Of Contents

Cancer Drug News 23 NOVEMBER 2015

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung ...

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

  • $ 6995
  • Industry report
  • November 2016
  • by Global Data

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident ...

2017-2021 US Tumor Marker Testing Market: Emerging Opportunities and Growth Strategies for Suppliers

2017-2021 US Tumor Marker Testing Market: Emerging Opportunities and Growth Strategies for Suppliers

  • $ 6400
  • Industry report
  • February 2017
  • by Venture Planning Group

Complete report $9,800.  DataPack (test volumes, sales forecasts, supplier shares) $6,400. Highlights Comprehensive 620-page analysis of the US tumor marker testing market.Major issues pertaining to the ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.